Epclusa
E413592
Epclusa is a prescription antiviral medication used to treat chronic hepatitis C infection across all major genotypes.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Epclusa canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T4050932 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Epclusa Context triple: [Gilead Sciences, product, Epclusa]
-
A.
Harvoni
Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
-
B.
Sovaldi
Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.
-
C.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
D.
Descovy
Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.
-
E.
Truvada
Truvada is a prescription antiretroviral medication widely used both to treat HIV infection and as pre-exposure prophylaxis (PrEP) to help prevent HIV in high-risk individuals.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Epclusa Target entity description: Epclusa is a prescription antiviral medication used to treat chronic hepatitis C infection across all major genotypes.
-
A.
Harvoni
Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
-
B.
Sovaldi
Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.
-
C.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
D.
Descovy
Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.
-
E.
Truvada
Truvada is a prescription antiretroviral medication widely used both to treat HIV infection and as pre-exposure prophylaxis (PrEP) to help prevent HIV in high-risk individuals.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
antiviral medication
ⓘ
direct-acting antiviral ⓘ fixed-dose combination drug ⓘ prescription drug ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| ATCCode | J05AP55 ⓘ |
| canBeUsedWith | ribavirin in certain patients with decompensated cirrhosis ⓘ |
| containsDoseOfSofosbuvir | 400 mg ⓘ |
| containsDoseOfVelpatasvir | 100 mg ⓘ |
| contraindicatedWith |
strong CYP2B6 inducers
ⓘ
strong CYP2C8 inducers ⓘ strong CYP3A4 inducers ⓘ strong P-gp inducers ⓘ |
| developer |
Gilead Sciences
ⓘ
linked to:
Gilead Sciences (board member)
|
| dosageForm | film-coated tablet ⓘ |
| eliminationRoute |
biliary excretion of velpatasvir
ⓘ
renal excretion of sofosbuvir metabolite ⓘ |
| FDAApprovalYear | 2016 ⓘ |
| hasActiveIngredient |
sofosbuvir
ⓘ
velpatasvir ⓘ |
| hasBrandName | Epclusa ⓘ |
| hasCommonAdverseEffect |
anemia when used with ribavirin
ⓘ
fatigue ⓘ headache ⓘ insomnia ⓘ nausea ⓘ |
| hasGenericName | sofosbuvir and velpatasvir ⓘ |
| hasIndication | pan-genotypic hepatitis C treatment ⓘ |
| indicatedFor |
adults with chronic hepatitis C
ⓘ
pediatric patients 3 years and older with chronic hepatitis C ⓘ |
| legalStatusInUnitedStates | prescription only ⓘ |
| manufacturer |
Gilead Sciences
ⓘ
linked to:
Gilead Sciences (board member)
|
| mechanismOfAction |
NS5A inhibition via velpatasvir
ⓘ
NS5B polymerase inhibition via sofosbuvir ⓘ |
| metabolism | primarily hepatic ⓘ |
| pregnancyCategory | requires risk–benefit assessment, especially with ribavirin ⓘ |
| requiresMonitoringOf |
HCV RNA levels
ⓘ
hepatitis B virus reactivation risk ⓘ liver function tests ⓘ |
| routeOfAdministration | oral ⓘ |
| takenOnce | daily ⓘ |
| treats |
chronic hepatitis C virus infection
ⓘ
hepatitis C genotype 1 ⓘ hepatitis C genotype 2 ⓘ hepatitis C genotype 3 ⓘ hepatitis C genotype 4 ⓘ hepatitis C genotype 5 ⓘ hepatitis C genotype 6 ⓘ |
| typicalTreatmentDuration | 12 weeks ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Epclusa Description of subject: Epclusa is a prescription antiviral medication used to treat chronic hepatitis C infection across all major genotypes.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.